Q BioMed Inc (OTCMKTS:QBIO) Is Today's Biotech Focus

Q BioMed Inc (OTCMKTS:QBIO) is the latest biotech runner to take the OTC Markets by storm. Shares have exploded off the $1.26 lows in July to hit $6 this month. The stock has benefited from exposure on Financial News Media's network and research reports from SeeThruEquity, which issued a price target of $3.85 back in July and just raised its price target to $6. Investors are now asking if this biotech runner can keep climbing.First up, a little background on the company. Q BioMed Inc (formerly ISMO Tech Solutions, Inc.) was incorporated in the State of Nevada on November 22, 2013. The company describes itself as "a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns via organic growth, out-licensing, sale or spinoff new public companies."In early September, QBIO acquired an exclusive license and option agreement for a FDA approved generic drug, Strontium Chloride ("SR89"). This licensed radiopharmaceutical agent is indicated for the treatment of pain associated with metastatic bone cancer. SR89 provides long lasting relief for patients suffering from bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. The drug is preferentially absorbed in bone metastases, it has been proven to provide a long-term effect resulting in non--narcotic cancer pain relief and enhanced quality of life.There are approximately 300,000 new cases of bone metastases in patients with breast and lung cancer per year in the U.S. alone. Approximately 80% of patients using SR89 have reported experiencing a substantial decrease in pain, an increase in physical activity and a reduction in the need for opiate analgesics, such as morphine. QBIO CEO Denis Corin said:

"We are very excited about the potential for this drug and look forward to bringing it to market as quickly as possible, delivering significant value to all stakeholders, including current and future patients. The revenue we hope to realize will be a significant milestone for us and substantially derisks our business. However, over and above the near term revenue, we are particularly enthusiastic about the opportunities for growth to increase the potential revenue exponentially."

Besides SR89, QBIO's other asset is MAN-01, which is for the treatment of glaucoma. Glaucoma affects 60 million people annually. This number is expected to grow to 100 million by the year 2020. The current market opportunity for the treatment of glaucoma is nearly $5 billion with no new treatment options over the last 20 years.QBIO acquired the license for MAN-01 from Mannin Research. Mannin Research is progressing well in its pre-clinical lead candidate optimization of a small molecule for a topical route of administration. Mannin is continuing strategic partnership discussions with companies and technologies that will strengthen Mannin's intellectual property portfolio in the Tie2/TEK mechanism of action market. Mannin is also establishing research and development partnerships with non-governmental organizations to provide direct support for the MAN-01 program.QBIO also says that it has been conducting due diligence on several other potential assets to expand the ophthalmology pipeline within Q BioMed. These include implantable devices and biomarker diagnostics. With its cancer palliation drug expected to start generating revenue in less than 12 months, QBIO will have the cash to make these acquisitions without having to dilute shareholders.Currently trading with a market cap of $37 million, QBIO is an exciting story among small cap biotech plays. The key with QBIO will be management executing the company's plan. Here, investors are in luck. CEO Denis Corin is the former CEO of TapImmune Inc (OTCMKTS:TPIV), a clinical stage immune-oncology company. TPIV has been a favorite of ours here at Insider Financial. With the former CEO of TPIV at the helm of QBIO, we will be watching this one closely. We will be updating our subscribers as soon as we know more. For the latest updates on QBIO, sign up below!Disclosure: We have no position in QBIO and have not been compensated for this article.